Dapagliflozin Tested in Anemic Adults With Chronic Kidney Disease
Tests dapagliflozin with anemia treatment in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 2
Where in Egypt
- Urology and Nephrology CenterAl Mansurah, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mansoura University
- Trial code
- NCT06897605
- Record updated
- 2 April 2025
- Original description
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.Read full original descriptionShow less
Clinical Study Evaluating the Impact of Dapagliflozin on Erythropoiesis-Stimulating Agent Responsiveness in Anemic Patients With Chronic Kidney Disease
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.
Inclusion: Adults aged ≥ 18 years with CKD stage III or IV; Patients with anemia of CKD and a hemoglobin level < 11.5 g/dL; Patients are receiving erythropoiesis-stimulating agent therapy.
Exclusion: Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial; Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes; Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma; Patients with current malignancies or a history of malignancy within the past 2 years; Patients with severe gastrointestinal bleeding; Diagnosed with pure red cell aplasia; Pregnant or lactating females.